Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid

We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidula, Neelima, Greenberg, Sally, Petrillo, Laura, Hwang, Jimmy, Melisko, Michelle, Goga, Andrei, Moasser, Mark, Magbanua, Mark, Park, John W., Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421499/
https://www.ncbi.nlm.nih.gov/pubmed/34489453
http://dx.doi.org/10.1038/s41523-021-00323-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421499/
https://www.ncbi.nlm.nih.gov/pubmed/34489453
http://dx.doi.org/10.1038/s41523-021-00323-8

Ejemplares similares